REFERENCES
- Abanades S, NoIla J, Rodriguez-Campello A, Pedro C, Valls A, Farre M. Reversible coma secondary to cefepime neu-rotoxicity. Ann Pharmacother. 2004; 38 (4): 606–8.
- Barbey F, Bugnon D, Wauters JP. Severe neurotoxicity of cefepime in uremic patients. Ann Intern Med. 2001;135 (11): 1011.
- Capparelli FJ, Diaz MF, Hlavnika A, Wainsztein NA, Lei-guarda R, Del Castillo ME. Cefepime- and cefixime-induced en-cephalopathy in a patient with normal renal function. Neurology. 2005; 65 (11): 1840.
- Garces EO, Andrade de Anzambuja MF, da Silva D, Bra-gatti JA, Jacoby T, Saldanha Thome F. Renal failure is a risk factor for cefepime-induced encephalopathy. J Nephrol. 2008; 21 (4): 526–34.
- Wong KM, Chan WK, Chan YH, Li CS. Cefepime-related neurotoxicity in a haemodialysis patient. Nephrol Dial Trans-plant. 1999; 14 (9): 2265–6.
- Chatellier D, Jourdain M, Mangalaboyi J, Ader F, Chopin C, Derambure P, et al. Cefepime-induced neurotoxicity: an un-derestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med. 2002; 28 (2): 214–7.
- Ferrara N, Abete P, Giordano M, Ferrara P, Carnovale V, Leosco D, et al. Neurotoxicity induced by Cefepime in a very old hemodialysis patient. Clin Nephrol. 2003; 59 (5): 388–90.
- Lin CS, Cheng CJ, Chou CH, Lin SH. Piperacillin/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis. Am J Med Sci. 2007 ; 333 (3): 181–4.
- Lam S, Gomolin IH. Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review. Pharma-cotherapy. 2006; 26 (8): 1169–74.
- Bresson J, Paugam-Burtz C, Josserand J, Bardin C, Mantz J, Pease S. Cefepime overdosage with neurotoxicity recovered by high-volume haemofiltration. J Antimicrob Chemother. 2008; 62 (4): 849–50.
- Yahav D, Paul M, Fraser A, Sand N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007; 7 (5): 338–48.
- Sonck J, Laureys G, Verbeelen D. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant. 2008; 23 (3): 966–70.
- Drago L, De Vecchi E. The safety of cefepime in the treat-ment of infection. Expert Opin Drug Saf. 2008; 7 (4): 377–87.
- Dakdouki GK, Al-Awar GN. Cefepime-induced en-cephalopathy. Int J Infect Dis. 2004; 8 (1): 59–61.
- Fernandez-Torre JL. Cefepime- and cefixime-induced en-cephalopathy in a patient with normal renal function. Neurology. 2006 25;67 (2): 367; author reply
- Sugimoto M, Uchida I, Mashimo T, Yamazaki S, Hatano K, Ikeda F, et al. Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. Neu-ropharmacology. 2003; 45 (3): 304–14.
- Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging. 2003; 20 (4): 289–302.
- Neu HC. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med. 1996; 100( 6A):685-755.
- Chow KM, Szeto CC, Hui AC, Wong TY, Li PK. Retro-spective review of neurotoxicity induced by cefepime and cef-tazidime. Pharmacotherapy. 2003; 23 (3): 369–73.